PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025
PolyPid (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, has scheduled its fourth quarter and full-year 2024 financial results and operational highlights announcement for Wednesday, February 12, 2025, before U.S. markets open.
The company will host a conference call and webcast at 8:30 AM Eastern Time to discuss results and provide business updates. Management recommends participants register at least 5 minutes before the call starts. Those not planning to ask questions are advised to join via webcast.
PolyPid (Nasdaq: PYPD), un'azienda biofarmaceutica in fase avanzata focalizzata sul miglioramento dei risultati chirurgici, ha programmato l'annuncio dei risultati finanziari del quarto trimestre e dell'intero anno 2024, insieme ai principali punti operativi, per mercoledì 12 febbraio 2025, prima dell'apertura dei mercati statunitensi.
L'azienda ospiterà una conferenza telefonica e una trasmissione web alle 8:30 AM ora orientale per discutere i risultati e fornire aggiornamenti aziendali. La direzione consiglia ai partecipanti di registrarsi almeno 5 minuti prima dell'inizio della chiamata. Coloro che non intendono porre domande sono invitati a partecipare tramite la trasmissione web.
PolyPid (Nasdaq: PYPD), una empresa biofarmacéutica en etapa avanzada centrada en mejorar los resultados quirúrgicos, ha programado el anuncio de sus resultados financieros del cuarto trimestre y del año completo 2024, así como los aspectos destacados operativos, para el miércoles 12 de febrero de 2025, antes de la apertura de los mercados en EE. UU.
La empresa llevará a cabo una llamada de conferencia y una transmisión web a las 8:30 AM hora del este para discutir resultados y proporcionar actualizaciones comerciales. La dirección recomienda a los participantes registrarse al menos 5 minutos antes de que comience la llamada. Se aconseja a quienes no planean hacer preguntas unirse a través de la transmisión web.
PolyPid (Nasdaq: PYPD)는 수술 결과 개선에 중점을 둔 후기 단계의 바이오 제약 회사로, 2025년 2월 12일 수요일에 2024년 4분기 및 전체 연도 재무 결과와 운영 하이라이트 발표를 예정하고 있습니다. 이는 미국 시장 개장 전에 이루어질 것입니다.
회사는 동부 표준시 기준 오전 8시 30분에 재무 결과를 논의하고 사업 업데이트를 제공하는 콘퍼런스 콜 및 웹캐스트를 개최할 예정입니다. 경영진은 참가자들이 통화 시작 5분 전까지 등록하는 것을 권장합니다. 질문을 하지 않을 계획인 경우 웹캐스트를 통해 참여하는 것이 좋습니다.
PolyPid (Nasdaq: PYPD), une entreprise biopharmaceutique en phase avancée axée sur l'amélioration des résultats chirurgicaux, a programmé l'annonce de ses résultats financiers du quatrième trimestre et de l'année 2024 ainsi que des éléments clés opérationnels pour le mercredi 12 février 2025, avant l'ouverture des marchés américains.
L'entreprise organisera une conférence téléphonique et un webinaire à 8h30, heure de l'Est, pour discuter des résultats et fournir des mises à jour sur les affaires. La direction recommande aux participants de s'inscrire au moins 5 minutes avant le début de l'appel. Ceux qui ne prévoient pas de poser des questions sont conseillés de rejoindre via le webinaire.
PolyPid (Nasdaq: PYPD), ein biopharmazeutisches Unternehmen in der späten Phase, das sich auf die Verbesserung der chirurgischen Ergebnisse konzentriert, hat die Ankündigung seiner finanziellen Ergebnisse für das vierte Quartal und das gesamte Jahr 2024 sowie der betrieblichen Höhepunkte auf Mittwoch, den 12. Februar 2025, vor der Eröffnung der US-Märkte festgelegt.
Das Unternehmen wird um 8:30 Uhr Eastern Time eine Telefonkonferenz und ein Webcast abhalten, um die Ergebnisse zu besprechen und Unternehmensupdates bereit zu stellen. Das Management empfiehlt den Teilnehmern, sich mindestens 5 Minuten vor Beginn der Konferenz anzumelden. Allen, die nicht vorhaben, Fragen zu stellen, wird geraten, über den Webcast teilzunehmen.
- None.
- None.
PETACH TIKVA, Israel, Jan. 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full-year 2024 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 12, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of management, the Company recommends listening via the webcast.
Conference Call Dial-In & Webcast Information:
| Date: | Wednesday, February 12, 2025 | |
| Time: | 8:30 AM Eastern Time | |
| Conference | ||
| Call: | https://register.vevent.com/register/BI4e72dffa5a7b4167a28a33a6b3097df3 | |
| Webcast | https://edge.media-server.com/mmc/p/7uzqoye3 | |
About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.
For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.
References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.
Contacts:
PolyPid Ltd.
Ori Warshavsky
COO – US
908-858-5995
IR@Polypid.com
Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
Britchie@lifesciadvisors.com
FAQ
When will PolyPid (PYPD) release its Q4 and full-year 2024 earnings?
What time is PolyPid's (PYPD) Q4 2024 earnings call?
How can investors join PolyPid's (PYPD) Q4 2024 earnings call?
How early should participants register for PolyPid's (PYPD) Q4 2024 earnings call?
